- Home
- VGI vs ASMB Comparison
VGI vs ASMB Comparison
Compare VGI & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | ASMB |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.7M | 512.1M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | VGI | ASMB |
|---|---|---|
| Price | $6.72 | $22.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $52.00 |
| AVG Volume (30 Days) | 42.6K | ★ 292.3K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.66 | $21.80 |
| 52 Week High | $8.04 | $39.71 |
Technical Indicators
Market Signals| Indicator | VGI | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 25.87 | 27.24 |
| Support Level | N/A | $21.80 |
| Resistance Level | $7.99 | $30.36 |
| Average True Range (ATR) | 0.12 | 1.22 |
| MACD | -0.02 | -0.41 |
| Stochastic Oscillator | 16.36 | 1.75 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.